• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童心肌病基因检测的产出:对新型治疗方案的影响

Yield of Genetic Testing in Pediatric Cardiomyopathies: Implications for Novel Therapeutic Options.

作者信息

Ballerini Adelaide, Girolami Francesca, Gozzini Alessia, Passantino Silvia, Zampieri Mattia, Marchi Alberto, Tomberli Alessia, Calabri Giovanni B, Spaziani Gaia, Porcedda Giulio, Bennati Elena, Favilli Silvia, Olivotto Iacopo

机构信息

Cardiogenetic Unit, Meyer Children's Hospital IRCCS, Florence, Italy.

Cardiology Unit, Meyer Children's Hospital IRCCS, Florence, Italy.

出版信息

Mol Genet Genomic Med. 2025 Jul;13(7):e70119. doi: 10.1002/mgg3.70119.

DOI:10.1002/mgg3.70119
PMID:40642871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12246793/
Abstract

Pediatric cardiomyopathies are rare, heterogeneous, and challenging conditions, often with a genetic etiology. We estimated the yield of genetic testing in a pediatric cohort with cardiomyopathies and evaluated the potential candidacy to current or emerging treatments based on genetic results. Over one-third had a conclusive genetic test, including 25% of potential candidates for emerging precision therapies or developing pharmacological options.

摘要

小儿心肌病是罕见、异质性且具有挑战性的病症,通常具有遗传病因。我们估计了小儿心肌病队列中基因检测的阳性率,并根据基因检测结果评估了当前或新兴治疗方法的潜在适用性。超过三分之一的患者进行了确定性基因检测,其中25%是新兴精准疗法或开发药物选择的潜在候选者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299d/12246793/4aa057d97635/MGG3-13-e70119-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299d/12246793/4aa057d97635/MGG3-13-e70119-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/299d/12246793/4aa057d97635/MGG3-13-e70119-g001.jpg

相似文献

1
Yield of Genetic Testing in Pediatric Cardiomyopathies: Implications for Novel Therapeutic Options.儿童心肌病基因检测的产出:对新型治疗方案的影响
Mol Genet Genomic Med. 2025 Jul;13(7):e70119. doi: 10.1002/mgg3.70119.
2
Genetic testing in cardiomyopathies: updates and future perspectives.心肌病的基因检测:最新进展与未来展望
J Cardiovasc Med (Hagerstown). 2025 Jul 1;26(7):386-397. doi: 10.2459/JCM.0000000000001750. Epub 2025 Jun 20.
3
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.Elucigene FH20 和 LIPOchip 用于家族性高胆固醇血症的诊断:系统评价和经济评估。
Health Technol Assess. 2012;16(17):1-266. doi: 10.3310/hta16170.
4
Spinal Muscular Atrophy脊髓性肌萎缩症
5
Genetic testing in early-onset atrial fibrillation.早发性心房颤动的基因检测。
Eur Heart J. 2024 Sep 7;45(34):3111-3123. doi: 10.1093/eurheartj/ehae298.
6
Treatments for intractable constipation in childhood.儿童难治性便秘的治疗方法。
Cochrane Database Syst Rev. 2024 Jun 19;6(6):CD014580. doi: 10.1002/14651858.CD014580.pub2.
7
Parent training interventions for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 5 to 18 years.针对5至18岁儿童注意力缺陷多动障碍(ADHD)的家长培训干预措施。
Cochrane Database Syst Rev. 2011 Dec 7;2011(12):CD003018. doi: 10.1002/14651858.CD003018.pub3.
8
Interventions for self-harm in children and adolescents.儿童和青少年自我伤害的干预措施。
Cochrane Database Syst Rev. 2015 Dec 21;2015(12):CD012013. doi: 10.1002/14651858.CD012013.
9
Diagnostic Yield of Next-Generation Sequencing for Rare Pediatric Genetic Disorders: A Single-Center Experience.下一代测序技术对儿童罕见遗传病的诊断率:单中心经验
Med Sci (Basel). 2025 Jun 9;13(2):75. doi: 10.3390/medsci13020075.
10
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.慢性阻塞性肺疾病的长效吸入疗法(β受体激动剂、抗胆碱能药物和类固醇):一项网状荟萃分析。
Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2.

本文引用的文献

1
Towards etiological treatments in cardiomyopathies.针对心肌病的病因治疗。
Presse Med. 2024 Mar;53(1):104223. doi: 10.1016/j.lpm.2024.104223. Epub 2024 Feb 2.
2
Applications of Gene Therapy in Cardiomyopathies.基因治疗在心肌病中的应用。
JACC Heart Fail. 2024 Feb;12(2):248-260. doi: 10.1016/j.jchf.2023.09.015. Epub 2023 Oct 7.
3
Novel therapeutic perspectives in Noonan syndrome and RASopathies.努南综合征和 RAS 病相关疾病的新治疗视角。
Eur J Pediatr. 2024 Mar;183(3):1011-1019. doi: 10.1007/s00431-023-05263-y. Epub 2023 Oct 21.
4
The clinical utility of pediatric cardiomyopathy genetic testing: From diagnosis to a precision medicine-based approach to care.儿童心肌病基因检测的临床应用:从诊断到基于精准医学的护理方法。
Prog Pediatr Cardiol. 2021 Sep;62. doi: 10.1016/j.ppedcard.2021.101413. Epub 2021 Jul 1.
5
Cardiomyopathy in Children: Classification and Diagnosis: A Scientific Statement From the American Heart Association.儿童心肌病:分类与诊断——美国心脏协会科学声明
Circulation. 2019 Jul 2;140(1):e9-e68. doi: 10.1161/CIR.0000000000000682. Epub 2019 May 28.